Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy
- Maria D Cao†1, 8Email author,
- Guro F Giskeødegård†1,
- Tone F Bathen1, 2,
- Beathe Sitter1, 2,
- Anna Bofin3,
- Per E Lønning4, 5,
- Steinar Lundgren1, 6, 7 and
- Ingrid S Gribbestad1
© Cao et al; licensee BioMed Central Ltd. 2012
Received: 20 September 2011
Accepted: 25 January 2012
Published: 25 January 2012
Today's clinical diagnostic tools are insufficient for giving accurate prognosis to breast cancer patients. The aim of our study was to examine the tumor metabolic changes in patients with locally advanced breast cancer caused by neoadjuvant chemotherapy (NAC), relating these changes to clinical treatment response and long-term survival.
Patients (n = 89) participating in a randomized open-label multicenter study were allocated to receive either NAC as epirubicin or paclitaxel monotherapy. Biopsies were excised pre- and post-treatment, and analyzed by high resolution magic angle spinning magnetic resonance spectroscopy (HR MAS MRS). The metabolite profiles were examined by paired and unpaired multivariate methods and findings of important metabolites were confirmed by spectral integration of the metabolite peaks.
All patients had a significant metabolic response to NAC, and pre- and post-treatment spectra could be discriminated with 87.9%/68.9% classification accuracy by paired/unpaired partial least squares discriminant analysis (PLS-DA) (p < 0.001). Similar metabolic responses were observed for the two chemotherapeutic agents. The metabolic responses were related to patient outcome. Non-survivors (< 5 years) had increased tumor levels of lactate (p = 0.004) after treatment, while survivors (≥ 5 years) experienced a decrease in the levels of glycine (p = 0.047) and choline-containing compounds (p ≤ 0.013) and an increase in glucose (p = 0.002) levels. The metabolic responses were not related to clinical treatment response.
The differences in tumor metabolic response to NAC were associated with breast cancer survival, but not to clinical response. Monitoring metabolic responses to NAC by HR MAS MRS may provide information about tumor biology related to individual prognosis.
The prognosis of patients with locally advanced breast cancer varies largely due to the heterogeneity of the disease, and 5-year survival rates from 50 to 80% have been reported . Neoadjuvant chemotherapy (NAC) has been established as a standard treatment for locally advanced breast cancer, with anthracyclines and taxanes being among the most frequently used agents. NAC is provided to make primarily inoperable tumors resectable, and will also increase the rate of breast-conserving surgery without any significant increase in local or distal recurrence [2, 3]. Studies investigating the metabolic responses and chemoresistance to single or a combination of drugs are important for effective treatment and better patient outcome.
Patients with a pathological complete response (pCR) after NAC have improved outcome compared to patients with residual disease, thus treatment response is a prognostic indicator. However, only ~20% of patients will achieve a pCR to NAC . Other prognostic factors of breast cancer include axillary lymph node status, tumor size, Her-2 overexpression, histopathological grade, and hormone receptor status. The status of Her-2 and hormone receptors is also predictive of treatment response. Identification of other markers for prognosis and treatment response may help stratify patients for better individualized treatment.
Several studies have shown altered metabolism in cancer compared to normal tissue. Elevated levels of total choline-containing compounds (tCho) are frequently observed in cancer, and may serve as magnetic resonance spectroscopy (MRS) markers for malignancy, both in vivo and ex vivo [5, 6]. The tCho signal constitutes signals from glycerophosphocholine (GPC), phosphocholine (PC) and free choline (Cho) which are involved in phospholipid metabolism through the Kennedy pathway. A decreased level of tCho detected by in vivo MRS has been suggested as a possible marker for treatment response [7, 8]. Altered concentrations of other tissue metabolites, such as increased levels of lactate, have also been associated with malignancy [9, 10]. Elevated lactate levels may be related to hypoxia, a common feature of solid tumors where glucose is catabolised to lactate due to the lack of oxygen. Also under conditions with sufficient oxygen levels, cancer cells may convert glucose to lactate, described as the Warburg effect.
High resolution magic angle spinning (HR MAS) MRS is a non-destructive technique providing highly resolved MR spectra of intact tissues with minimal sample preparation. HR MAS MR spectra provide an overview of the different metabolites that are present in a tissue sample, and can give insight into the complex processes leading to cancer and other diseases. More than 30 metabolites have been identified in breast tissue using HR MAS MRS . Systematic studies of the metabolic state of biological systems using multivariate analysis methods are referred to as metabolomics. MR metabolomics studies of breast cancer have revealed correlations between tissue metabolic profiles and clinical prognostic factors such as hormone receptor status, grade and lymphatic spread [12–14]. Long-term survival of breast cancer patients has been successfully predicted from breast cancer tissue using multivariate classification models . The purpose of this study was to examine the metabolic changes in breast cancer tissues resulting from treatment with NAC, and to relate these changes to treatment response and long-term survival. This is the first study to investigate the metabolic response of NAC in a large breast cancer cohort using ex vivo MRS.
Patient and tumor characteristics
We examined a subcohort of breast cancer patients (n = 89) from a larger open-label multicenter study where patients were randomly allocated to receive NAC treatment with either anthracycline (epirubicin, 90 mg/m2) or taxane (paclitaxel, 200 mg/m2) monotherapy . The patients were given subsequent adjuvant endocrine treatment according to guidelines from the Norwegian Breast Cancer Group. The inclusion criteria and treatment protocol are fully described elsewhere . Briefly, female breast cancer patients at pre/post menopausal age (≤ 70 years) with locally advanced (stage III, T3/4 and/or N2) non-inflammatory breast cancer with or without limited distant metastasis were recruited in the period 1997-2003. The patients were treated every third week for four cycles. Patients showing a non-satisfactory response were assigned to the opposite treatment. From each patient, an incisional biopsy was taken before treatment with NAC and a post-treatment biopsy was excised during surgical removal of the tumor. The biopsies were immediately snap-frozen and stored in -80°C and subsequently in liquid nitrogen in a biobank until use. A part of the pre-treatment tumor biopsy was obtained for routine pathological diagnosis and hormone status assignment. Estrogen (ER) and progesterone receptor (PgR) status were determined by immunohistochemical staining (positive ≥ 10% staining cells). The study was approved by The Regional Committee for Medical and Health Research Ethics (Norwegian Health Region III) and informed written consent was obtained from all patients
Response and survival evaluation
Response to treatment was evaluated using the WHO criteria by the UICC system . Treatment response was assessed clinically by comparing caliper measurements prior to NAC treatment and after the last cycle. In the subcohort included in this study, the patients were classified to have either partial response (≥ 50% reduction in tumor size (the product of the two largest tumor diameters) after treatment, but not complete response) or stable disease (< 50% reduction to ≤ 25% increase in tumor size after treatment). Patients deceased within 5 years after diagnosis were classified as non-survivors whereas patients surviving 5 years or more were classified as survivors.
Prior to HR MAS MRS analysis, imprint cytology smears were prepared from the tissue samples and stained with the May-Grünwald-Giemsa stain (Color-Rapid, Med-Kjemi, Norway). Confirmation of tumor cell content was determined microscopically by a cytopathologist.
HR MAS MRS experiments
HR MAS MRS analyses were performed on a Bruker Avance DRX600 spectrometer (Bruker Biospin GmbH, Germany) equipped with a 1H/13 C MAS probe with gradient. The run order of the samples was randomized http://www.random.org and blindly analyzed during 18 days. Each sample (15.1 ± 2.8 mg) was cut to fit a 30 μl leak-proof disposable insert (Bruker Biospin Corp, USA) and added phosphate buffered saline (PBS, 3 μl) in D2O containing trimethylsilyl tetradeuteropropionic acid (TSP, 98.2 mM) for chemical shift referencing. Samples were spun at 5 kHz and spectra were recorded within 31 min per sample at 4°C to minimize tissue degradation. Spin-echo spectra (cpmgpr; Bruker) were recorded as previously described .
Patient and tumor characteristics
(n = 60)
(n = 23)
(n = 2)
Mean age (± SD)
51.1 ± 10.6
49.3 ± 8.3
46.4 ± 2.6
Mean tumor dimensions (mean ± SD)
67.9 × 67.9 ± 18.0 × 19.8
78.6 × 77.3 ± 22.0 × 24.0
65.0 × 51.5 ± 7.1 × 26.2
Multivariate data analysis
Partial least squares (PLS) analysis is a regression method for analysis of collinear data with numerous variables. The method is based on extraction of underlying structures, or latent variables (LVs), that maximize the covariance between X (the spectra) and a response variable Y . PLS discriminant analysis (PLS-DA) attempts to discriminate between distinct classes. PLS-DA was performed in Matlab R2009a (The Mathworks, Inc., USA) using PLS_Toolbox 6.2.1 (Eigenvector Research, USA). A PLS-DA model was built on mean-centred spectra from randomly chosen training samples (90% of the patients) and used to predict the status of test samples (the remaining 10%). This procedure was repeated 20 times and the average classification results were calculated. The number of LVs to use was chosen by cross-validation of the whole data set and used for all repetitions to avoid biased results. The importance of each variable in the loadings of the PLS-DA was evaluated by variable importance in the projection (VIP) scores . The VIP score positively reflects the variable's influence on the classification, and variables with a score greater than one are generally considered important [21, 22]. To evaluate the statistical significance of the classification results, permutation testing was performed . In permutation testing, the class labels are permuted to resemble random classification. It is then possible to examine if the achieved prediction results of the original data set are significantly different than random predictions. The data set with the permuted class label was divided into training and test sets repeated 20 times as described for the original data set, and the average results were calculated. The permutation procedure was repeated 1,000 times, and the prediction error of the original data set was compared to the distribution of prediction errors from the permutation. P-values ≤ 0.05 were considered significant.
where the matrix A represents pre-treatment spectra, and matrix B represents the post-treatment spectra.
Univariate data analysis
To further validate the important metabolites from the PLS-DA models, relative intensities were found by integrating the peak areas of spectra normalized to equal total areas after removal of lipid residuals (Matlab R2009a, The Mathworks, Inc., USA). Normalization of spectra with the lipid residual signals removed will correct for differences in sample size and tumor cell content, as it can be assumed that most of the lipid signals from breast samples do not originate from cancer cells. Group differences were statistically tested by Wilcoxon rank sum tests or Wilcoxon sign rank for paired analyses, and considered significant if the p-values were ≤ 0.05.
Metabolic response to neoadjuvant chemotherapy
Classification results from multilevel PLS-DA and PLS-DA
No. of LVs
Control vs Treatment
(n = 65p)
Control vs Treatment
(n = 37p)
Control vs Treatment
(n = 28p)
Control vs Treatment
(n = 44p)
Control vs Treatment
(n = 19p)
(n = 65p)
Partial response vs
(n = 48)
(n = 32)
Partial response vs
(n = 41)
(n = 29)
(n = 57)
(n = 20)
(n = 47)
(n = 21)
(n = 29)
(n = 23)
No differences in metabolic response between clinical response groups
The patients were divided into two groups according to their clinical response (partial response or stable disease), and multilevel PLS-DA was performed on each group separately in order to discover potential differences in metabolic treatment response between the groups. Both for patients with partial response and stable disease there was a significant change in the tumor metabolism in response to NAC treatment, and treatment spectra could be discriminated from controls with a sensitivity and specificity ≥ 80.0%. The metabolic response to NAC as observed in the loading plots was similar for both subgroups, resembling the changes observed for the whole data set (results not shown). Thus, no difference in the metabolic response could be detected between patients with stable disease and partial response.
Different metabolic responses correlate with survival
The patients were also divided into two groups according to their survival status (5-year survivors or non-survivors). Both for survivors and non-survivors there was a clear change in the tumor metabolism in response to NAC treatment (Figure 1B and 1C), and treatment spectra could be discriminated from controls with a sensitivity and specificity ≥ 82.5%. However, the metabolic treatment response appears to differ between survivors and non-survivors.
Changes in relative intensities of metabolites in response to NAC
Survivors (n = 44)
Non-survivors (n = 19)
Mean ± SE
Mean ± SE
2.8 ± 15.3
97.1 ± 26.4
-19.6 ± 8.0
0.8 ± 14.3
-59.6 ± 14.6
-11.8 ± 15.7
-95.4 ± 24.3
-67.4 ± 44.2
-16.6 ± 6.3
-17.8 ± 6.3
-167.2 ± 36.7
-95.3 ± 57.5
-0.8 ± 13.2
6.9 ± 12.5
17.8 ± 5.1
-0.2 ± 8.8
Glycine appears to be decreased in survivors according to the loadings, and the difference in relative intensities before and after treatment was significant (p = 0.047). For non-survivors, the glycine level appears to be high in some samples from both the control and the treatment group; hence the role of glycine in the loading plot is more difficult to interpret. The glycine change from integrated relative intensities was not significant in non-survivors, with a mean value close to zero.
GPC levels were decreased in the loading plot of survivors with VIP scores showing high importance, while changes in GPC levels in non-survivors were less important for the discrimination. Accordingly, the relative intensities of GPC were significantly lower in response to treatment in survivors (p < 0.001) but not in non-survivors.
The loadings show decreased levels of PC in response to treatment in both survivors and non-survivors. However, the change in PC relative intensities was only significant for survivors (p < 0.001), but not for non-survivors, possibly due to a high standard error.
Relative intensities of Cho levels were significantly decreased in survivors (p = 0.013) in response to treatment, but only a trend of decreased Cho levels was seen in non-survivors (p = 0.084). In addition, glucose was significantly increased in survivors (p = 0.002). Cho and glucose were not protruding in the loadings, possibly due to low intensity values.
As an overall measure of the partly overlapping choline-containing metabolite peaks (GPC, PC, and Cho), the changes in relative intensities of tCho were calculated. Survivors had a significant decrease in tCho levels in response to treatment (p < 0.001), while a trend of decreased tCho levels were detected in non-survivors (p = 0.091).
Metabolic traits at pre- and post-treatment
Relative intensities of metabolites at pre- and post-treatment
Pre-treatment (mean ± SE)
Post-treatment (mean ± SE)
185.8 ± 11.4
164.6 ± 13.8
196.2 ± 12.7
250.6 ± 26.0
115.0 ± 6.4
120.8 ± 11.0
91.2 ± 4.1
111.4 ± 8.4
167.3 ± 12.4
170.1 ± 23.9
115.6 ± 6.7
153.9 ± 24.1
247.9 ± 17.0
285.4 ± 34.9
158.0 ± 16.1
205.5 ± 28.1
95.4 ± 3.9
108.7 ± 8.3
79.5 ± 3.7
85.9 ± 6.2
498.3 ± 26.4
551.3 ± 46.8
344.9 ± 22.3
434.6 ± 44.6
242.6 ± 9.6
222.8 ± 12.4
248.0 ± 8.1
222.3 ± 9.3
48.4 ± 3.3
49.3 ± 6.0
63.6 ± 4.3
53.5 ± 6.6
The metabolic differences between survivor and non-survivors were not seen pre-treatment as the multivariate model could not discriminate the two outcome groups (model not valid). Furthermore, none of the metabolites showed significant differences in relative intensities between survivors and non-survivors pre-treatment (Table 4).
No significant differences in the metabolite profiles at pre- or post-treatment were detected between patients with partial responders and stable disease by PLS-DA. Post-treatment spectra from patients treated with Epirubicin and Paclitaxel could not be discriminated by PLS-DA, further confirming the similarity of the metabolic response of the two chemotherapeutic agents that were used in this study.
In this study we examined the metabolic effect of NAC treatment in patients with locally advanced breast cancer. By comparing MR spectra of biopsies taken pre- and post-treatment, significant metabolic changes in response to treatment were found both by paired and unpaired multivariate models. The results using paired multilevel PLS-DA were however superior to those of unpaired PLS-DA, thus taking advantage of the multilevel structure in the data set was clearly beneficial.
Epirubicin and Paclitaxel appear to affect the metabolism of the tumor cells in the same manners, as evidenced both by indistinguishable metabolic responses and similar metabolic traits of the post-treatment spectra. Anthracyclines work by inducing damage to the DNA, while taxanes stabilize the microtubules; thereby inhibiting cell division [26, 27]. However, both treatments will eventually result in cell death. This might explain why the two agents appear to have similar metabolic responses.
Interestingly, all patients in our study cohort experienced changes in the metabolite profiles in response to treatment, including also patients categorized to have a clinically stable disease. No differences in the metabolic responses of the clinical response groups were detected. However, when examining the metabolic changes in survivors and non-survivors independently, a difference in the metabolic response to NAC was seen. Non-survivors had a significant increase in lactate levels in response to treatment, while survivors showed no change in lactate levels. As a result, a trend of higher levels of lactate was detected in non-survivors compared to survivors post-treatment. Increased lactate levels may be a marker for tumor aggressiveness as high levels of lactate have been correlated with low survival rates, high incidence of distant metastasis and recurrence, and increased risk of radiation resistance in several types of cancer [28–30]. Modification of cell energy metabolism is typically observed in malignant tumors and is suggested as an emerging hallmark of cancer . Under normoxic conditions, cancer cells can reprogram their energy metabolism to largely depend on aerobic glycolysis as their primary energy pathway resulting in increased lactate production; the so-called Warburg effect. It is not fully known why cancer cells prefer aerobic glycolysis over complete oxidation as this would produce far more ATP. It has been hypothesized that lactate may enhance the invasiveness of tumor cells and the resulting low pH may help tumor cells evade tumor-attacking immune cells .
In addition to aerobic glycolysis, breast cancer cells are often hypoxic due to poor blood supply . It can be assumed that the large tumors of patients with locally advanced breast cancer will be affected by hypoxia. Hypoxia can induce the transcription factor hypoxia inducible factor-1α (HiF-1α), which in turn upregulates multiple genes involved in the glycolytic pathway, angiogenesis, cell proliferation, and other mechanisms [33–35]. Furthermore HIF-1α promotes transcription of lactate dehydrogenase (LDH) and lactate monocarboxylate transporters (MCT), and thus plays an important role in the production and efflux of lactate in cancer cells [36, 37]. Inhibition of LDH by small interfering RNA (siRNA) in mouse breast tumors has been shown to reduce the glycolytic activity associated with a decrease in tumor proliferation and tumorigenic potential . Thus we can suggest that the increased levels of lactate after NAC treatment observed in non-survivors may reflect enhancement of aerobic glycolytic activity and/or hypoxic tumor responses that confer higher tumor malignancy and poor prognosis. In addition, the glucose levels were increased in response to treatment in survivors but not in non-survivors. Studies using 18F- FDG PET have shown decreased glucose uptake in tumors after treatment with chemotherapy [39, 40]. The increased glucose level observed in survivors after NAC may therefore be indicative of decreased aerobic glycolysis and tumor hypoxic response favorable of long term breast cancer survival.
Survivors had a significant decrease in glycine as a response to treatment, while it remained unchanged in non-survivors. This was reflected in the post-treatment spectra, showing significantly lower levels of glycine in survivors. In a previous study of patients receiving NAC with the anthracycline doxorubicin, we also found decreased glycine levels after NAC to be associated with long term breast cancer survival . The biological role of glycine in tumor malignancy is still unclear. Several studies have elucidated the biomarker potential of glycine in human brain tumors, where it was found to positively correlate with tumor grade [41, 42]. Higher levels of glycine have also been detected in pre-clinical studies of the more aggressive basal-like breast cancer model compared to the luminal-like model . In patients, high glycine levels detected in malignant breast tumors have been correlated with poor prognosis . Glycine is mainly synthesized from 3-phosphoglycerate, an intermediate of the glycolysis. In addition, glycine can be synthesized from Cho through the glycine-betaine pathway. We can postulate that the decreased glycine levels after NAC treatment detected in survivors are caused by altered glycolysis and/or reduced Cho levels associated with reduced tumor aggressiveness.
A significant decrease of GPC, PC, Cho levels and the combined tCho level was detected in survivors in response to treatment, whereas non-survivors experienced only a trend of decrease in Cho and tCho levels. As a result, lower tCho levels in survivors compared to non-survivors post-treatment approached significance. In a previous publication, we showed that GPC and Cho concentrations significantly decreased in patients with long-term survival (≥ 5 years), while non-survivors (< 5 years) had no significant changes in choline phospholipid metabolites in response to doxorubicin . Choline phospholipid metabolites are important biological compounds in cell membrane synthesis and turnover. In addition, tCho levels have been associated with increased malignancy and activation of oncogenic signaling in breast cancer cells [45, 46]. Higher tCho concentrations have been detected in high-grade breast tumors and tumors with higher pharmacokinetic parameters measured with dynamic contrast enhanced MR imaging, indicating a correlation between choline phospholipid metabolism and tumor malignancy and angiogenesis [47, 48]. As previously mentioned, cancer cells may undergo adaptive responses to hypoxia by inducing HiF-1α. Increased tCho levels and choline kinase alpha (CHKA) expressions have been detected in prostate cancer cells and xenografts models under hypoxic compared to normoxic conditions . In the same study, the authors found hypoxic tumor regions to be co-localized with regions of high tCho, which possibly occurred through the up-regulation of CHKA by HiF-1α. CHKA is known to play an important role in malignant transformation in several types of cancer . Overexpression of CHKA and elevated PC and tCho levels of breast cancer cells have been associated with increased invasiveness and drug resistance . Decreased choline phospholipid metabolism after NAC treatment may be associated with lower malignancy that potentially can be used as a predictor of breast cancer survival.
The metabolic responses to NAC treatment appear to be similar in patients with partial response and stable disease. None of the patients in this study had a progressive disease, whereas patients with a complete response would not have any tumor tissue left for a post-treatment biopsy. By definition the group with stable disease can have up to 50% reduction in tumor volume, and indeed only two patients in this study had an equal or increased tumor size after NAC. In that respect, almost all patients had a biological effect of the treatment although the tumor reduction was small for patients with a stable disease. It is conceivable that a cohort including also patients with progressive disease would reveal clearer differences in metabolic response between the clinical response groups. It is however noteworthy that all patients in this study in general had a decrease in tCho after NAC, as tCho is suggested as an in vivo biomarker for clinical treatment response. Using current in vivo systems, the different choline-containing compounds can not be separated by 1H MRS, and metabolites such as lactate and glycine are not visible using standard in vivo protocols. Ex vivo studies can therefore provide information that is not achievable in current clinical in vivo systems. However, future technological improvements of in vivo systems and the implementation of spectral editing and hyperpolarization techniques can enable the translation of ex vivo findings into in vivo clinical use.
In this patient cohort, the prediction of overall survival was accomplished with 70.1% classification accuracy using post-treatment spectra, but no prognostic information could be extracted from the pre-treatment spectra. This shows that the difference between survivors and non-survivors post-treatment results from a metabolic response to the treatment. The observed higher levels of lactate and glycine in non-survivors compared to survivors support our previous studies postulating high lactate and glycine levels to be predictive of low breast cancer survival rates (< 5 years).
The tissue samples examined in this study have been stored in liquid nitrogen since 1997-2003. However, no significant metabolite degradation due to storage time has been reported using HR MAS MRS . In addition, the tissue samples were prepared on ice and MR experiments were performed at 4°C which will reduce the degradation process. The metabolic patterns observed in this study should therefore not be affected by sample storage and preparation.
Prediction of survival in patients receiving NAC is challenging. As NAC will downstage and potentially completely remove the disease, standard prognostic indicators such as tumor size and lymph node status are no longer fully applicable after NAC. Several studies have shown that a pathological complete response after NAC is associated with better survival rates . However, approximately 80% of patients will have residual tumor in the breast after treatment . Our study shows that the metabolic response to treatment may be an indicator of patient prognosis.
By comparing HR MAS MR spectra from biopsies excised before and after NAC treatment, we have revealed significant metabolic changes in breast cancer tumors as a response to treatment. Different metabolic responses could be related to patient outcome, but did not separate patients with partial response from those with stable disease after treatment. Non-survivors had increased tumor levels of lactate after treatment, while survivors experienced a decrease in the levels of glycine and choline-containing compounds. These differences in tumor response may reflect tumor aggressiveness associated with breast cancer survival. Monitoring metabolic responses to NAC by HR MAS MRS may provide information about tumor biology related to prognosis, and help identify pathways for targeted therapies.
This study was supported by the Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU), and the Norwegian Research Council grant no. 10324400 (MDC) and 183379 (GFG).
- Mathew J, Asgeirsson KS, Cheung KL, Chan S, Dahda A, Robertson JF: Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions. Eur J Surg Oncol. 2009, 35 (2): 113-122. 10.1016/j.ejso.2008.03.015.View ArticlePubMed
- Makhoul I, Kiwan E: Neoadjuvant systemic treatment of breast cancer. J Surg Oncol. 2011, 103 (4): 348-357. 10.1002/jso.21696.View ArticlePubMed
- Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, Nash AG, Ford HT: A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol. 1998, 9 (11): 1179-1184. 10.1023/A:1008400706949.View ArticlePubMed
- Kong X, Moran MS, Zhang N, Haffty B, Yang Q: Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer. 2011, Corrected Proof,
- Ackerstaff E, Glunde K, Bhujwalla ZM: Choline phospholipid metabolism: a target in cancer cells?. J Cell Biochem. 2003, 90 (3): 525-533. 10.1002/jcb.10659.View ArticlePubMed
- Katz-Brull R, Lavin PT, Lenkinski RE: Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst. 2002, 94 (16): 1197-1203. 10.1093/jnci/94.16.1197.View ArticlePubMed
- Baek H-M, Chen J-H, Nalcioglu O, Su M-Y: Proton MR spectroscopy for monitoring early treatment response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol. 2008, 19 (5): 1022-1024. 10.1093/annonc/mdn121.PubMed CentralView ArticlePubMed
- Jagannathan NR, Kumar M, Seenu V, Coshic O, Dwivedi SN, Julka PK, Srivastava A, Rath GK: Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer. 2001, 84 (8): 1016-1022. 10.1054/bjoc.2000.1711.PubMed CentralView ArticlePubMed
- Cheng LL, Chang IW, Smith BL, Gonzalez RG: Evaluating human breast ductal carcinomas with high-resolution magic-angle spinning proton magnetic resonance spectroscopy. J Magn Reson. 1998, 135 (1): 194-202. 10.1006/jmre.1998.1578.View ArticlePubMed
- Tessem MB, Swanson MG, Keshari KR, Albers MJ, Joun D, Tabatabai ZL, Simko JP, Shinohara K, Nelson SJ, Vigneron DB, Gribbestad IS, Kurhanewicz J: Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn Reson Med. 2008, 60 (3): 510-516. 10.1002/mrm.21694.PubMed CentralView ArticlePubMed
- Sitter B, Sonnewald U, Spraul M, Fjosne HE, Gribbestad IS: High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed. 2002, 15 (5): 327-337. 10.1002/nbm.775.View ArticlePubMed
- Bathen TF, Jensen LR, Sitter B, Fjosne HE, Halgunset J, Axelson DE, Gribbestad IS, Lundgren S: MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res Treat. 2007, 104 (2): 181-189. 10.1007/s10549-006-9400-z.View ArticlePubMed
- Giskeødegård GF, Grinde MT, Sitter B, Axelson DE, Lundgren S, Fjøsne HE, Dahl S, Gribbestad IS, Bathen TF: Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. J Proteome Res. 2010, 9 (2): 972-979. 10.1021/pr9008783.View ArticlePubMed
- Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS: Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed. 2006, 19 (1): 30-40. 10.1002/nbm.992.View ArticlePubMed
- Cao MD, Sitter B, Bathen TF, Bofin A, Lonning PE, Lundgren S, Gribbestad IS: Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling. NMR Biomed. 2012, 25 (2): 369-378. 10.1002/nbm.1762. doi: 10.1002/nbm.1762. Epub 2011 Aug 8View ArticlePubMed
- Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Østenstad B, Lundgren S, Risberg T, Mjaaland I, Skjønsberg G, Aas T, Schlichting E, Fjösne HE, Nysted A, Lillehaug JR, Lønning PE: Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with Epirubicin or Paclitaxel. PLoS ONE. 2011, 6 (4): e19249-10.1371/journal.pone.0019249.PubMed CentralView ArticlePubMed
- Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD: Assessment of response to therapy in advanced breast cancer. Cancer. 1977, 39 (3): 1289-1294. 10.1002/1097-0142(197703)39:3<1289::AID-CNCR2820390340>3.0.CO;2-F.View ArticlePubMed
- Eilers PHC: Parametric Time Warping. Anal Chem. 2004, 76: 404-411. 10.1021/ac034800e.View ArticlePubMed
- Savorani F, Tomasi G, Engelsen SB: icoshift: a versatile tool for the rapid alignment of 1D NMR spectra. J Magn Reson. 2010, 202 (2): 190-202. 10.1016/j.jmr.2009.11.012.View ArticlePubMed
- Wold S, Sjöström M, Eriksson L: PLS-regression: a basic tool of chemometrics. Chemometrics Intell Lab Syst. 2001, 58 (2): 109-130. 10.1016/S0169-7439(01)00155-1.View Article
- Chong I-G, Jun C-H: Performance of some variable selection methods when multicollinearity is present. Chemometrics Intell Lab Syst. 2005, 78 (1-2): 103-112. 10.1016/j.chemolab.2004.12.011.View Article
- Chen J, Wang W, Lv S, Yin P, Zhao X, Lu X, Zhang F, Xu G: Metabonomics study of liver cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations. Anal Chim Acta. 2009, 650 (1): 3-9. 10.1016/j.aca.2009.03.039.View ArticlePubMed
- Westerhuis J, Hoefsloot H, Smit S, Vis D, Smilde A, van Velzen E, van Duijnhoven J, van Dorsten F: Assessment of PLSDA cross validation. Metabolomics. 2008, 4 (1): 81-89. 10.1007/s11306-007-0099-6.View Article
- van Velzen EJJ, Westerhuis JA, van Duynhoven JPM, van Dorsten FA, Hoefsloot HCJ, Jacobs DM, Smit S, Draijer R, Kroner CI, Smilde AK: Multilevel data analysis of a crossover designed human nutritional intervention study. J Proteome Res. 2008, 7 (10): 4483-4491. 10.1021/pr800145j.View ArticlePubMed
- Westerhuis JA, van Velzen EJ, Hoefsloot HC, Smilde AK: Multivariate paired data analysis: multilevel PLSDA versus OPLSDA. Metabolomics. 2010, 6 (1): 119-128. 10.1007/s11306-009-0185-z.PubMed CentralView ArticlePubMed
- Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L: Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004, 56 (2): 185-229. 10.1124/pr.56.2.6.View ArticlePubMed
- McGrogan BT, Gilmartin B, Carney DN, McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2008, 1785 (2): 96-132. 10.1016/j.bbcan.2007.10.004.View Article
- Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW, Mueller-Klieser W: Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001, 51 (2): 349-353. 10.1016/S0360-3016(01)01630-3.View ArticlePubMed
- Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfør K, Rofstad EK, Mueller-Klieser W: High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res. 2000, 60 (4): 916-921.PubMed
- Quennet V, Yaromina A, Zips D, Rosner A, Walenta S, Baumann M, Mueller-Klieser W: Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol. 2006, 81 (2): 130-135. 10.1016/j.radonc.2006.08.012.View ArticlePubMed
- Hanahan D, Weinberg Robert A: Hallmarks of cancer: the next generation. Cell. 2011, 144 (5): 646-674. 10.1016/j.cell.2011.02.013.View ArticlePubMed
- Locasale J, Cantley L: Altered metabolism in cancer. BMC Biology. 2010, 8 (1): 88-PubMed CentralView ArticlePubMed
- Brown N, Bicknell R: Hypoxia and oxidative stress in breast cancer: oxidative stress--its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res. 2001, 3 (5): 323-327. 10.1186/bcr315.PubMed CentralView ArticlePubMed
- Vander Heiden MG, Cantley LC, Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009, 324 (5930): 1029-1033. 10.1126/science.1160809.PubMed CentralView ArticlePubMed
- Duffy M, Maguire T, Hill A, McDermott E, O'Higgins N: Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000, 2: 252-257. 10.1186/bcr65.PubMed CentralView ArticlePubMed
- Mathupala S, Colen C, Parajuli P, Sloan A: Lactate and malignant tumors: a therapeutic target at the end stage of glycolysis. J Bioenerg Biomembr. 2007, 39 (1): 73-77. 10.1007/s10863-006-9062-x.PubMed CentralView ArticlePubMed
- Weidemann A, Johnson RS: Biology of HIF-1alpha. Cell Death Differ. 2008, 15 (4): 621-627. 10.1038/cdd.2008.12.View ArticlePubMed
- Fantin VR, St-Pierre J, Leder P: Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006, 9 (6): 425-434. 10.1016/j.ccr.2006.04.023.View ArticlePubMed
- Duch J, Fuster D, Muñoz M, Fernández P, Paredes P, Fontanillas M, Guzmán F, Rubí S, Lomeña F, Pons F: 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2009, 36 (10): 1551-1557. 10.1007/s00259-009-1116-y.View ArticlePubMed
- Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, Ricaud M, Bourbouloux E, Doutriaux I, Clouet M, Berton-Rigaud D, Bouriel C, Delecroix V, Garin E, Rouquette S, Resche I, Kerbrat P, Chatal JF, Campone M: Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]Fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2006, 24 (34): 5366-5372. 10.1200/JCO.2006.05.7406.View ArticlePubMed
- Davies NP, Wilson M, Natarajan K, Sun Y, MacPherson L, Brundler MA, Arvanitis TN, Grundy RG, Peet AC: Non-invasive detection of glycine as a biomarker of malignancy in childhood brain tumours using in-vivo1H MRS at 1.5 Tesla confirmed by ex-vivo high-resolution magic-angle spinning NMR. NMR Biomed. 2010, 23 (1): 80-87. 10.1002/nbm.1432.View ArticlePubMed
- Righi V, Andronesi OC, Mintzopoulos D, Black PM, Tzika AA: High-resolution magic angle spinning magnetic resonance spectroscopy detects glycine as a biomarker in brain tumors. Int J Oncol. 2010, 36 (2): 301-306.PubMed CentralPubMed
- Moestue S, Borgan E, Huuse E, Lindholm E, Sitter B, Børresen-Dale A, Engebraaten O, Mælandsmo G, Gribbestad I: Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC cancer. 2010, 10 (1): 433-10.1186/1471-2407-10-433.PubMed CentralView ArticlePubMed
- Sitter B, Bathen TF, Singstad TE, Fjøsne HE, Lundgren S, Halgunset J, Gribbestad IS: Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed. 2010, 23 (4): 424-431.PubMed
- Aboagye EO, Bhujwalla ZM: Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res. 1999, 59 (1): 80-84.PubMed
- Ronen SM, Jackson LE, Beloueche M, Leach MO: Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3 T3 cells. Br J Cancer. 2001, 84 (5): 691-696. 10.1054/bjoc.2000.1663.PubMed CentralView ArticlePubMed
- Baek H-M, Yu HJ, Chen J-H, Nalcioglu O, Su M-Y: Quantitative correlation between 1H MRS and dynamic contrast-enhanced MRI of human breast cancer. Magn Reson Imaging. 2008, 26 (4): 523-531. 10.1016/j.mri.2007.10.002.View ArticlePubMed
- Chen JH, Mehta RS, Baek HM, Nie K, Liu H, Lin MQ, Yu HJ, Nalcioglu O, Su MY: Clinical characteristics and biomarkers of breast cancer associated with choline concentration measured by 1H MRS. NMR Biomed. 2011, 24 (3): 316-324. 10.1002/nbm.1595.PubMed CentralView ArticlePubMed
- Glunde K, Shah T, Winnard PT, Raman V, Takagi T, Vesuna F, Artemov D, Bhujwalla ZM: Hypoxia regulates choline kinase expression through Hypoxia-Inducible Factor-1α signaling in a human prostate cancer model. Cancer Res. 2008, 68 (1): 172-180. 10.1158/0008-5472.CAN-07-2678.View ArticlePubMed
- de Molina AR, Báñez-Coronel M, Gutiérrez R, Rodríguez-González A, Olmeda D, Megías D, Lacal JC: Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res. 2004, 64 (18): 6732-6739. 10.1158/0008-5472.CAN-04-0489.View Article
- Shah T, Wildes F, Penet M-F, Winnard PT, Glunde K, Artemov D, Ackerstaff E, Gimi B, Kakkad S, Raman V, Bhujwalla ZM: Choline kinase overexpression increases invasiveness and drug resistance of human breast cancer cells. NMR Biomed. 2010, 23 (6): 633-642. 10.1002/nbm.1510.PubMed CentralView ArticlePubMed
- Jordan K, He W, Halpern E, Wu C, Cheng L: Evaluation of tissue metabolites with high resolution magic angle spinning MR spectroscopy human prostate samples after three-year storage at -80°C. Biomarker Insights. 2007, 2: 147-PubMed CentralPubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/39/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited